Evidence map›Paper›PMID 30139286›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2018

Ethenesulfonyl fluoride derivatives as telomerase inhibitors: structure-based design, SAR, and anticancer evaluation in vitro.

Xing Chen, Gao-Feng Zha, Jie Quan Wang, Xin-Hua Liu

Open access · goldAbstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Structure-activity relationship,Journal of enzyme inhibition and medicinal chemistry · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Xing Chena School of Pharmacy, Anhui Province Key Laboratory of Major Autoimmune Diseases , Anhui Institute of Innovative Drugs, Anhui Medical University , Hefei , P. R. China.
Gao-Feng Zhab School of Chemistry, Chemical Engineering and Life Science , Wuhan University of Technology , Wuhan , P. R. China.
Jie Quan Wanga School of Pharmacy, Anhui Province Key Laboratory of Major Autoimmune Diseases , Anhui Institute of Innovative Drugs, Anhui Medical University , Hefei , P. R. China.
Xin-Hua Liua School of Pharmacy, Anhui Province Key Laboratory of Major Autoimmune Diseases , Anhui Institute of Innovative Drugs, Anhui Medical University , Hefei , P. R. China.
Anhui Medical University · CNWuhan University of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Based on our previous docking model, in order to carry out more rational drug design, totally 82 vinyl sulfonyl fluorides, including some 2-(hetero)arylethenesulfonyl fluorides and 1,3-dienylsulfonyl fluorides derivatives as potential human telomerase inhibitors were designed and synthesised. The in vitro anticancer activity assay showed that compound 57 (1E,3E)-4-(4-((E)-2-(fluorosulfonyl)vinyl)phenyl)buta-1,3-diene-1-sulfonyl fluoride exhibited high activity against A375 and MDA-MB-231 cell lines with IC

Indexed as

Drug DesignAntineoplastic AgentsCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorEnzyme InhibitorsEthylenesFluoridesHumansMolecular StructureStructure-Activity RelationshipSulfhydryl CompoundsTelomeraseAntineoplastic AgentsEnzyme InhibitorsethyleneEthylenesFluoridesSulfhydryl CompoundsTelomeraseEthenesulfonyl fluorideinhibitorselective anticancer activitytelomerase

Identifiers

PMID30139286
PMCPMC6116703
OpenAlexW2888334570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.